NSAA
Prostatic Neoplasms
University of SydneyPhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 73/ 100
Competitive context
73 Active assets in the Prostatic Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel Merck Sharp & Dohme LLC | Phase 4 | BBB |
Degarelix Novartis Pharmaceuticals | Phase 4 | BBB |
PREDNISONE TABLETS Merck Sharp & Dohme LLC | Phase 3 | BBB |
LEUPROLIDE Dana-Farber Cancer Institute | Phase 4 | BB |
Abiraterone Acetate Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →